2023-03-16 ゲーテ大学
A painful rash, red spots and blisters on the skin – possible signs of infection with Mpox or monkeypox virus.
Goethe大学とケント大学の科学者によるマルチサイト研究の一環として特定され、その研究結果により臨床試験が近いうちに開始される予定である。ニトロキソリンは、mpoxウイルスの複製を抑制することが既に示された抗ウイルス薬とは異なり、複数のウイルスや細菌の同時に抑制することができるため、mpox治療の有望な代替手段として注目されている。また、従来から医療に使用されている抗生物質であり、副作用も少ないため、臨床試験で直接mpoxに対して試験することができる。
<関連情報>
- https://aktuelles.uni-frankfurt.de/english/known-active-ingredient-as-new-drug-candidate-against-monkeypox/
- https://onlinelibrary.wiley.com/doi/10.1002/jmv.28652
抗生物質NitroxolineのMpox治療への再利用 Repurposing of the antibiotic nitroxoline for the treatment of mpox
Denisa Bojkova, Nadja Zöller, Manuela Tietgen, Katja Steinhorst, Marco Bechtel, Tamara Rothenburger, Joshua D. Kandler, Julia Schneider, Victor M. Corman, Sandra Ciesek, Holger F. Rabenau, Mark N. Wass, Stefan Kippenberger, Stephan Göttig, Martin Michaelis, Jindrich Cinatl jr
Journal of Medical Virology Published: 10 March 2023
DOI:https://doi.org/10.1002/jmv.28652
Abstract
The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence. Moreover, their use is affected by toxic side-effects (brincidofovir, cidofovir), limited availability (tecovirimat), and potentially by resistance formation. Hence, additional, readily available drugs are needed. Here, therapeutic concentrations of nitroxoline, a hydroxyquinoline antibiotic with a favourable safety profile in humans, inhibited the replication of 12 mpox virus isolates from the current outbreak in primary cultures of human keratinocytes and fibroblasts and a skin explant model by interference with host cell signalling. Tecovirimat, but not nitroxoline, treatment resulted in rapid resistance development. Nitroxoline remained effective against the tecovirimat-resistant strain and increased the anti-mpox virus activity of tecovirimat and brincidofovir. Moreover, nitroxoline inhibited bacterial and viral pathogens that are often co-transmitted with mpox. In conclusion, nitroxoline is a repurposing candidate for the treatment of mpox due to both antiviral and antimicrobial activity.
This article is protected by copyright. All rights reserved.
